Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Mar;84(5):604–610. doi: 10.1054/bjoc.2000.1637

Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study

F Doz 1, J C Gentet 2, F Pein 3, D Frappaz 4, P Chastagner 5, S Moretti 1, G Vassal 3, J Arditti 6, O Van Tellingen 7, A Iliadis 8, J Catalin 8
PMCID: PMC2363793  PMID: 11237379

Abstract

The maximum tolerated dose of paclitaxel administered by 24-hour continuous infusion in children is known. Short infusion might offer equivalent antitumour efficacy and reduced haematological toxicity, without increasing the allergic risk. Our aims were to determine the maximum tolerated dose and the pharmacokinetics of paclitaxel in children when administered in 3-h infusion every 3 weeks. Patients older than 6 months, younger than 20 years with refractory malignant solid tumours were eligible when they satisfied standard haematological, renal, hepatic and cardiologic inclusion criteria with life expectancy exceeding 8 weeks. Paclitaxel was administered as a 3-hour infusion after premedication (dexamethasone, dexchlorpheniramine). Pharmacokinetic analysis and solvent assays (ethanol, cremophor) were performed during the first course. 20 courses were studied in 17 patients; 4 dosage levels were investigated (240 to 420 mg/m2). No dose-limiting haematological toxicity was observed. Severe acute neurological and allergic toxicity was encountered. One treatment-related death occurred just after the infusion at the highest dosage. Delayed peripheral neurotoxicity and moderate allergic reactions were also encountered. Pharmacokinetic analysis showed dose-dependent clearance of paclitaxel and elevated blood ethanol and Cremophor EL levels. Although no limiting haematological toxicity was reached, we do not recommend this paclitaxel schedule in children because of its acute neurological toxicity. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: paclitaxel, short-term infusion, phase 1, children

Full Text

The Full Text of this article is available as a PDF (86.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adinoff B., Bone G. H., Linnoila M. Acute ethanol poisoning and the ethanol withdrawal syndrome. Med Toxicol Adverse Drug Exp. 1988 May-Jun;3(3):172–196. doi: 10.1007/BF03259881. [DOI] [PubMed] [Google Scholar]
  2. Cavaletti G., Bogliun G., Marzorati L., Zincone A., Marzola M., Colombo N., Tredici G. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer. 1995 Mar 1;75(5):1141–1150. doi: 10.1002/1097-0142(19950301)75:5<1141::aid-cncr2820750514>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  3. Chapuis B., Helg C., Jeannet M., Zulian G., Huber P., Gumovski P. Anaphylactic reaction to intravenous cyclosporine. N Engl J Med. 1985 May 9;312(19):1259–1259. doi: 10.1056/NEJM198505093121915. [DOI] [PubMed] [Google Scholar]
  4. Eiseman J. L., Eddington N. D., Leslie J., MacAuley C., Sentz D. L., Zuhowski M., Kujawa J. M., Young D., Egorin M. J. Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol. 1994;34(6):465–471. doi: 10.1007/BF00685656. [DOI] [PubMed] [Google Scholar]
  5. Eisenhauer E. A., ten Bokkel Huinink W. W., Swenerton K. D., Gianni L., Myles J., van der Burg M. E., Kerr I., Vermorken J. B., Buser K., Colombo N. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994 Dec;12(12):2654–2666. doi: 10.1200/JCO.1994.12.12.2654. [DOI] [PubMed] [Google Scholar]
  6. Gaspard M. H., Maraninchi D., Stoppa A. M., Gastaut J. A., Michel G., Tubiana N., Blaise D., Novakovitch G., Rossi J. F., Weiller P. J. Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies. Cancer Chemother Pharmacol. 1988;22(3):256–262. doi: 10.1007/BF00273421. [DOI] [PubMed] [Google Scholar]
  7. Gianni L., Kearns C. M., Giani A., Capri G., Viganó L., Lacatelli A., Bonadonna G., Egorin M. J. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol. 1995 Jan;13(1):180–190. doi: 10.1200/JCO.1995.13.1.180. [DOI] [PubMed] [Google Scholar]
  8. Glantz M. J., Choy H., Kearns C. M., Cole B. F., Mills P., Zuhowski E. G., Saris S., Rhodes C. H., Stopa E., Egorin M. J. Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. J Clin Oncol. 1996 Feb;14(2):600–609. doi: 10.1200/JCO.1996.14.2.600. [DOI] [PubMed] [Google Scholar]
  9. Glantz M. J., Choy H., Kearns C. M., Mills P. C., Wahlberg L. U., Zuhowski E. G., Calabresi P., Egorin M. J. Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. J Natl Cancer Inst. 1995 Jul 19;87(14):1077–1081. doi: 10.1093/jnci/87.14.1077. [DOI] [PubMed] [Google Scholar]
  10. Glück S., Germond C., Lopez P., Cano P., Dorreen M., Koski T., Arnold A., Dulude H., Gallant G. A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer. Eur J Cancer. 1998 Jun;34(7):1008–1014. doi: 10.1016/s0959-8049(97)10168-x. [DOI] [PubMed] [Google Scholar]
  11. Huizing M. T., Keung A. C., Rosing H., van der Kuij V., ten Bokkel Huinink W. W., Mandjes I. M., Dubbelman A. C., Pinedo H. M., Beijnen J. H. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol. 1993 Nov;11(11):2127–2135. doi: 10.1200/JCO.1993.11.11.2127. [DOI] [PubMed] [Google Scholar]
  12. Hurwitz C. A., Relling M. V., Weitman S. D., Ravindranath Y., Vietti T. J., Strother D. R., Ragab A. H., Pratt C. B. Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study. J Clin Oncol. 1993 Dec;11(12):2324–2329. doi: 10.1200/JCO.1993.11.12.2324. [DOI] [PubMed] [Google Scholar]
  13. Kearns C. M., Gianni L., Egorin M. J. Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol. 1995 Jun;22(3 Suppl 6):16–23. [PubMed] [Google Scholar]
  14. Koch-Weser J., Sellers E. M., Kalant H. Alcohol intoxication and withdrawal. N Engl J Med. 1976 Apr 1;294(14):757–762. doi: 10.1056/NEJM197604012941405. [DOI] [PubMed] [Google Scholar]
  15. Landers D. F. Alcoholic coma and some associated conditions. Am Fam Physician. 1983 Oct;28(4):219–222. [PubMed] [Google Scholar]
  16. Lansky S. B., List M. A., Lansky L. L., Ritter-Sterr C., Miller D. R. The measurement of performance in childhood cancer patients. Cancer. 1987 Oct 1;60(7):1651–1656. doi: 10.1002/1097-0142(19871001)60:7<1651::aid-cncr2820600738>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  17. Litovitz T. The alcohols: ethanol, methanol, isopropanol, ethylene glycol. Pediatr Clin North Am. 1986 Apr;33(2):311–323. doi: 10.1016/s0031-3955(16)35004-0. [DOI] [PubMed] [Google Scholar]
  18. Magalini S. C., Nanni G., Agnes S., Citterio F., Castagneto M. Anaphylactic reaction to first exposure to cyclosporine. Transplantation. 1986 Oct;42(4):443–444. [PubMed] [Google Scholar]
  19. Martin N., Catalin J., Blachon M. F., Durand A. Assay of paclitaxel (Taxol) in plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1998 May 29;709(2):281–288. doi: 10.1016/s0378-4347(98)00060-7. [DOI] [PubMed] [Google Scholar]
  20. McLeod H. L., Baker D. K., Jr, Pui C. H., Rodman J. H. Somnolence, hypotension, and metabolic acidosis following high-dose teniposide treatment in children with leukemia. Cancer Chemother Pharmacol. 1991;29(2):150–154. doi: 10.1007/BF00687326. [DOI] [PubMed] [Google Scholar]
  21. Moss M. H. Alcohol-induced hypoglycemia and coma caused by alcohol sponging. Pediatrics. 1970 Sep;46(3):445–447. [PubMed] [Google Scholar]
  22. Namouni F., Doz F., Tanguy M. L., Quintana E., Michon J., Pacquement H., Bouffet E., Gentet J. C., Plantaz D., Lutz P. High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: a SFOP and SFGM study. Eur J Cancer. 1997 Dec;33(14):2368–2375. doi: 10.1016/s0959-8049(97)10019-3. [DOI] [PubMed] [Google Scholar]
  23. Nolte H., Carstensen H., Hertz H. VM-26 (teniposide)-induced hypersensitivity and degranulation of basophils in children. Am J Pediatr Hematol Oncol. 1988 Winter;10(4):308–312. doi: 10.1097/00043426-198824000-00007. [DOI] [PubMed] [Google Scholar]
  24. Rischin D., Webster L. K., Millward M. J., Linahan B. M., Toner G. C., Woollett A. M., Morton C. G., Bishop J. F. Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. J Natl Cancer Inst. 1996 Sep 18;88(18):1297–1301. doi: 10.1093/jnci/88.18.1297. [DOI] [PubMed] [Google Scholar]
  25. Rowinsky E. K., Donehower R. C. Paclitaxel (taxol) N Engl J Med. 1995 Apr 13;332(15):1004–1014. doi: 10.1056/NEJM199504133321507. [DOI] [PubMed] [Google Scholar]
  26. Schiller J. H., Storer B., Tutsch K., Arzoomanian R., Alberti D., Feierabend C., Spriggs D. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol. 1994 Feb;12(2):241–248. doi: 10.1200/JCO.1994.12.2.241. [DOI] [PubMed] [Google Scholar]
  27. Seibel N. L., Blaney S. M., O'Brien M., Krailo M., Hutchinson R., Mosher R. B., Balis F. M., Reaman G. H. Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial. Clin Cancer Res. 1999 Apr;5(4):733–737. [PubMed] [Google Scholar]
  28. Seidman A. D., Tiersten A., Hudis C., Gollub M., Barrett S., Yao T. J., Lepore J., Gilewski T., Currie V., Crown J. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol. 1995 Oct;13(10):2575–2581. doi: 10.1200/JCO.1995.13.10.2575. [DOI] [PubMed] [Google Scholar]
  29. Sonnichsen D. S., Hurwitz C. A., Pratt C. B., Shuster J. J., Relling M. V. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol. 1994 Mar;12(3):532–538. doi: 10.1200/JCO.1994.12.3.532. [DOI] [PubMed] [Google Scholar]
  30. Sonnichsen D. S., Relling M. V. Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet. 1994 Oct;27(4):256–269. doi: 10.2165/00003088-199427040-00002. [DOI] [PubMed] [Google Scholar]
  31. Sparreboom A., van Tellingen O., Huizing M. T., Nooijen W. J., Beijnen J. H. Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1996 Jun 7;681(2):355–362. doi: 10.1016/0378-4347(95)00544-7. [DOI] [PubMed] [Google Scholar]
  32. Sparreboom A., van Tellingen O., Nooijen W. J., Beijnen J. H. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res. 1996 May 1;56(9):2112–2115. [PubMed] [Google Scholar]
  33. Sparreboom A., van Zuylen L., Brouwer E., Loos W. J., de Bruijn P., Gelderblom H., Pillay M., Nooter K., Stoter G., Verweij J. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 1999 Apr 1;59(7):1454–1457. [PubMed] [Google Scholar]
  34. Theis J. G., Liau-Chu M., Chan H. S., Doyle J., Greenberg M. L., Koren G. Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL. J Clin Oncol. 1995 Oct;13(10):2508–2516. doi: 10.1200/JCO.1995.13.10.2508. [DOI] [PubMed] [Google Scholar]
  35. Vassilomanolakis M., Tsoussis S., Efremidis A. Long lasting, grade IV, orthostatic hypotension after a single cycle combination chemotherapy with paclitaxel and cisplatin. Eur J Cancer. 1998 Jul;34(8):1295–1295. [PubMed] [Google Scholar]
  36. Webster L. K., Crinis N. A., Morton C. G., Millward M. J. Plasma alcohol concentrations in patients following paclitaxel infusion. Cancer Chemother Pharmacol. 1996;37(5):499–501. doi: 10.1007/s002800050419. [DOI] [PubMed] [Google Scholar]
  37. Wilson D. B., Beck T. M., Gundlach C. A. Paclitaxel formulation as a cause of ethanol intoxication. Ann Pharmacother. 1997 Jul-Aug;31(7-8):873–875. doi: 10.1177/106002809703100714. [DOI] [PubMed] [Google Scholar]
  38. Windebank A. J., Blexrud M. D., de Groen P. C. Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol Exp Ther. 1994 Feb;268(2):1051–1056. [PubMed] [Google Scholar]
  39. Younes A., Sarris A., Melnyk A., Romaguera J., McLaughlin P., Swan F., Rodriguez M. A., Hagemeister F., Moore D., North L. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1995 Mar;13(3):583–587. doi: 10.1200/JCO.1995.13.3.583. [DOI] [PubMed] [Google Scholar]
  40. van Tellingen O., Huizing M. T., Panday V. R., Schellens J. H., Nooijen W. J., Beijnen J. H. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer. 1999 Sep;81(2):330–335. doi: 10.1038/sj.bjc.6690696. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES